Raloxifene

Containing the active agent raloxifene, Evista® is used to treat and prevent osteoporosis in postmenopausal women. Daiichi Sankyo Europe bought the marketing and distribution rights for the osteoporosis brand Evista® from Eli Lilly.

Healthcare professionals can read more about the treatment and prevention of osteoporosis at: www.evista.eu

Patients can obtain more extensive information about osteoporosis, the risk factors for the disease and its prevention, including an individual risk calculator, at: www.osteoporosis-disease.eu